---
id: 239
title: Chronic Hepatitis C
category: clinical_syndromes
subcategory: viral
tags: [hepatitis-C, HCV, sofosbuvir-velpatasvir, DAA, SVR, cirrhosis]
difficulty: high
---

## Question

How is chronic hepatitis C managed? Use **"All Genotypes: Sofosbuvir-Velpatasvir × 12 Weeks, SVR >95%, Cure Achievable"** framework.

## Answer

### **Epidemiology:**

- **1.7 million infections** (US)
- **Leading indication** for liver transplant (historically)
- **Transmission:** Blood exposure (IVDU, transfusion pre-1992, needlestick, tattoos)
- **Genotypes:** 1-6 (genotype 1 most common in US, 75%)

### **Natural History:**

**Acute HCV:**
- **80%** develop chronic infection
- **20%** spontaneous clearance

**Chronic HCV (Untreated):**
- **20-30%** develop cirrhosis (over 20-30 years)
- **1-5%/year** risk of HCC (if cirrhosis)
- **3-6%/year** risk of decompensation (if cirrhosis)

### **Clinical Presentation:**

**Acute HCV:**
- **Often asymptomatic** (70%)
- **Mild symptoms:** Fatigue, jaundice (if symptomatic)

**Chronic HCV:**
- **Asymptomatic** for years/decades
- **Fatigue** (most common symptom)
- **Eventually:** Cirrhosis complications (ascites, variceal bleeding, encephalopathy, HCC)

**Extrahepatic Manifestations:**
- **Cryoglobulinemia** (vasculitis, purpura, arthralgia, glomerulonephritis)
- **Membranoproliferative glomerulonephritis**
- **Porphyria cutanea tarda**
- **Lichen planus**

### **Diagnosis:**

**Screening (Who to Test):**
- **All adults ≥18 years** (one-time screening, universal recommendation)
- **Pregnant women** (each pregnancy)
- **HIV-positive**
- **High-risk:** IVDU, hemodialysis, incarceration, tattoos, elevated ALT

**Two-Step Testing:**

**1. HCV Antibody (Anti-HCV):**
- **Screening test**
- **Positive = current OR past infection**

**2. HCV RNA (If Anti-HCV Positive):**
- **Confirms active infection**
- **Quantitative viral load** (IU/mL)
- **Genotype** (determines treatment regimen, though pangenotypic regimens now standard)

**HCV RNA Positive = Chronic HCV → Treat**

### **Pre-Treatment Evaluation:**

**Labs:**
- **HCV RNA, genotype**
- **CBC, CMP, INR**
- **HIV, HBV serology** (co-infection screening)

**Assess Fibrosis:**
- **Non-invasive:** FIB-4 score, transient elastography (FibroScan)
- **Liver biopsy:** Rarely needed (was historical gold standard)

**Cirrhosis Assessment:**
- **If cirrhosis → screen for HCC** (ultrasound + AFP q6 months)
- **If cirrhosis → screen for varices** (EGD)

### **Treatment:**

**All Patients with Chronic HCV Should Be Treated:**
- **Goal:** Sustained virologic response (SVR) = "cure"
- **SVR = Undetectable HCV RNA 12 weeks after treatment completion**

**Pan-Genotypic Regimens (First-Line):**

**Preferred (All Genotypes, Treatment-Naive, No Cirrhosis or Compensated Cirrhosis):**
- **Sofosbuvir-velpatasvir (Epclusa) 400mg/100mg PO daily × 12 weeks**
  - **SVR >95%**
  - **Pangenotypic** (genotypes 1-6)

**Alternative:**
- **Glecaprevir-pibrentasvir (Mavyret) 300mg/120mg (3 tabs) PO daily × 8 weeks** (if no cirrhosis)
  - **12 weeks** if compensated cirrhosis
  - **Pangenotypic**

**Decompensated Cirrhosis (Child-Pugh B/C):**
- **Sofosbuvir-velpatasvir 400mg/100mg + ribavirin** × 12 weeks
- **Coordinate with hepatology** (complex)

**Treatment-Experienced (Failed Prior DAA):**
- **Sofosbuvir-velpatasvir-voxilaprevir (Vosevi) 400mg/100mg/100mg PO daily × 12 weeks**
- **Consult hepatology**

**No Longer Recommended:**
- **Interferon-based regimens** (replaced by DAAs, cure rates >95% vs 40-50% with interferon)

### **Monitoring:**

**On Treatment:**
- **No routine monitoring** (well-tolerated, minimal side effects)
- **Check CBC, CMP at baseline** (rarely need follow-up labs)

**Post-Treatment:**
- **HCV RNA at 12 weeks** after completing treatment (assess for SVR)
- **If undetectable → CURED** (SVR >95%)

**If SVR Achieved:**
- **Reinfection possible** (if continued high-risk behavior like IVDU)
- **Monitor ALT annually** (if cirrhosis, continue HCC surveillance)

### **SVR (Sustained Virologic Response) = Cure:**

**Definition:** Undetectable HCV RNA 12 weeks after treatment completion

**Benefits:**
- **Prevents progression to cirrhosis** (if no cirrhosis)
- **Reduces HCC risk** (if cirrhosis, but risk persists, continue surveillance)
- **Reduces decompensation, mortality**
- **Resolves extrahepatic manifestations** (cryoglobulinemia)

**SVR Rates with DAAs:** **>95%** (nearly all patients cured)

### **Special Situations:**

**HIV/HCV Co-Infection:**
- **Same DAA regimens** (>95% SVR)
- **Check drug interactions** with ART

**HBV/HCV Co-Infection:**
- **Treat HCV first** (DAAs)
- **Monitor for HBV reactivation** (HBV DNA, ALT) during/after HCV treatment
- **May need HBV treatment** after HCV clearance

**Post-Transplant:**
- **Treat HCV** (prevents graft reinfection/damage)
- **Check drug interactions** with immunosuppressants

**Renal Insufficiency:**
- **Glecaprevir-pibrentasvir safe** (no renal dose adjustment)
- **Avoid sofosbuvir if CrCl <30** (not well-studied)

### **HCC Surveillance (If Cirrhosis):**

**Continue Surveillance After SVR:**
- **HCC risk reduced but persists** (especially if cirrhosis)
- **Ultrasound ± AFP q6 months** (lifelong if cirrhosis)

## Key Points

### **All Genotypes: Sofosbuvir-Velpatasvir × 12 Weeks:**
- **Pangenotypic, SVR >95%**
- **Well-tolerated, oral, short duration**

### **SVR = Cure:**
- **Undetectable HCV RNA 12 weeks post-treatment**
- **>95% cure rate** with DAAs

### **Universal Screening:**
- **All adults ≥18 years** (one-time)
- **Pregnant women** (each pregnancy)

### **Treat All Chronic HCV:**
- **Prevents cirrhosis, HCC, decompensation**
- **Nearly all patients can be cured**

### **HCC Surveillance Continues:**
- **If cirrhosis:** Ultrasound q6 months (lifelong, even after SVR)

### **Clinical Pearls:**
- **Sofosbuvir-velpatasvir (Epclusa) 400mg/100mg daily × 12 weeks** (pangenotypic, SVR >95%)
- **SVR = cure** (undetectable HCV RNA 12 weeks post-treatment)
- **Universal screening** (all adults ≥18 years)
- **Treat all chronic HCV** (cure achievable, prevents complications)
- **HCC surveillance:** Ultrasound q6 months (if cirrhosis, lifelong even after SVR)
- **Reinfection possible** (if continued IVDU)

## Sources

- [AASLD-IDSA: HCV Guidance 2024]
- [EASL: HCV Management 2024]

## Media

N/A
